GeneDx: Disappointing Q1 Creates Another Turnaround Opportunity

GeneDx Holdings Corp. specializes in advanced exome and genome diagnostic testing, leveraging its proprietary GeneDx Infinity dataset for superior interpretation. Q1 2026 results missed expectations, and guidance for the year was reduced primarily as a result of shifting product mix dynamics and delayed sales cycles. Blended test pricing was adversely impacted by the lower-priced, lower-margin genomic testing segment, which grew faster than anticipated.